Aravind Cherukuri1,2, David M Rothstein1,2,3. 1. Thomas E Starzl Transplantation Institute. 2. Renal and Electrolyte Division, Department of Medicine. 3. Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Abstract
PURPOSE OF THE REVIEW: Regulatory B cells (Bregs) play a prominent role in various disease settings. While progress has been hindered by the lack of a specific Breg marker, new findings highlight their role modulating the alloimmune response and promoting allograft survival. RECENT FINDINGS: Herein, we focus on the recent advances in Breg biology and their role in transplantation. We review studies showing that T-cell immunoglobulin and mucin domain 1 (TIM-1) is an inclusive and functional Breg marker in mice that may have human relevance. We highlight the utility of the B cell interleukin-10/tumor necrosis factor-alpha (IL-10/TNFα) ratio in identifying underlying immunological reactivity and predicting clinical outcomes in kidney transplantation. This may identify patients requiring more immunosuppression and provide insight into potential therapeutic approaches that can modulate the Breg: B effector cell (Beff) balance. SUMMARY: Emerging data support Bregs as potent modulators of immune responses in humans. Their ability to promote allograft survival must await development of approaches to expand Bregs in vitro/in vivo . The low IL-10/TNFα ratio reflecting decreased Breg/Beff balance, predicts acute rejection (AR) and poorer outcomes in renal transplantation. It remains to be determined whether this paradigm can be extended to other allografts and whether therapy aiming to correct the relative deficiency of Bregs will improve outcomes.
PURPOSE OF THE REVIEW: Regulatory B cells (Bregs) play a prominent role in various disease settings. While progress has been hindered by the lack of a specific Breg marker, new findings highlight their role modulating the alloimmune response and promoting allograft survival. RECENT FINDINGS: Herein, we focus on the recent advances in Breg biology and their role in transplantation. We review studies showing that T-cell immunoglobulin and mucin domain 1 (TIM-1) is an inclusive and functional Breg marker in mice that may have human relevance. We highlight the utility of the B cell interleukin-10/tumor necrosis factor-alpha (IL-10/TNFα) ratio in identifying underlying immunological reactivity and predicting clinical outcomes in kidney transplantation. This may identify patients requiring more immunosuppression and provide insight into potential therapeutic approaches that can modulate the Breg: B effector cell (Beff) balance. SUMMARY: Emerging data support Bregs as potent modulators of immune responses in humans. Their ability to promote allograft survival must await development of approaches to expand Bregs in vitro/in vivo . The low IL-10/TNFα ratio reflecting decreased Breg/Beff balance, predicts acute rejection (AR) and poorer outcomes in renal transplantation. It remains to be determined whether this paradigm can be extended to other allografts and whether therapy aiming to correct the relative deficiency of Bregs will improve outcomes.
Authors: Fernando G Cosio; Joseph P Grande; Hani Wadei; Timothy S Larson; Matthew D Griffin; Mark D Stegall Journal: Am J Transplant Date: 2005-10 Impact factor: 8.086
Authors: Stefanie Lindner; Karen Dahlke; Kai Sontheimer; Magdalena Hagn; Christof Kaltenmeier; Thomas F E Barth; Thamara Beyer; Frank Reister; Dorit Fabricius; Ramin Lotfi; Oleg Lunov; G Ulrich Nienhaus; Thomas Simmet; Rolf Kreienberg; Peter Möller; Hubert Schrezenmeier; Bernd Jahrsdörfer Journal: Cancer Res Date: 2013-02-05 Impact factor: 12.701
Authors: Aravind Cherukuri; Alan D Salama; Rajil Mehta; Kanishka Mohib; Leting Zheng; Ciara Magee; Mark Harber; Hans Stauss; Richard J Baker; Amit Tevar; Douglas Landsittel; Fadi G Lakkis; Sundaram Hariharan; David M Rothstein Journal: Sci Transl Med Date: 2021-02-24 Impact factor: 17.956
Authors: Menna R Clatworthy; Christopher J E Watson; Gemma Plotnek; Vicky Bardsley; Afzal N Chaudhry; J Andrew Bradley; Kenneth G C Smith Journal: N Engl J Med Date: 2009-06-18 Impact factor: 91.245
Authors: A Cherukuri; A D Salama; C Carter; N Smalle; R McCurtin; E W Hewitt; M Hernandez-Fuentes; B Clark; R J Baker Journal: Am J Transplant Date: 2012-03-05 Impact factor: 8.086
Authors: Aravind Cherukuri; David M Rothstein; Brendan Clark; Clive R Carter; Adam Davison; Maria Hernandez-Fuentes; Eric Hewitt; Alan D Salama; Richard J Baker Journal: J Am Soc Nephrol Date: 2014-03-07 Impact factor: 10.121
Authors: Tom A Barr; Ping Shen; Sheila Brown; Vicky Lampropoulou; Toralf Roch; Sarah Lawrie; Boli Fan; Richard A O'Connor; Stephen M Anderton; Amit Bar-Or; Simon Fillatreau; David Gray Journal: J Exp Med Date: 2012-04-30 Impact factor: 14.307